MARKET NEWS

Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement With ChemImage
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 
Ziopharm Oncology Completes Enrollment of Phase 1 Combination Trial
Theralase Announces Health Canada Approves Amended Clinical Trial Application
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA
Innate Pharma Announces Publication of Phase I Clinical Trial Results

  FEATURED EDITORIAL

  COMPANY PROFILE

Backed by over 85 years of experience in parenterals, Baxter’s BioPharma Solutions (BPS) business collaborates with pharmaceutical companies to support commercialization objectives for their molecules. BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing designed to meet complex and traditional sterile manufacturing challenges with confidence of delivery, service, and integrity. BPS can support your pharmaceutical needs with a broad portfolio of sterile fill/finish production capabilities, and our reputation is built on the high-quality products we manufacture for our clients in a cGMP environment. Click here for more.

  EXCLUSIVE ONLINE CONTENT

2019 Respiratory Drug Development eBook - Increased Focus on Respiratory Drug & Device Development Makes Treatment More Personal

2019 Respiratory Drug Development eBook - Increased Focus on Respiratory Drug & Device Development Makes Treatment More Personal

This e-Book highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.

Novavax & Catalent Biologics Enter Strategic Partnership

Novavax & Catalent Biologics Enter Strategic Partnership

Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit recently announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to……..

Dova Pharmaceuticals Announces FDA Approval of Supplemental NDA

Dova Pharmaceuticals Announces FDA Approval of Supplemental NDA

Dova Pharmaceuticals, Inc. recently announced the US FDA approved a supplemental New Drug Application (sNDA) that expands the use of DOPTELET (avatrombopag) to include the treatment of thrombocytopenia in adults with…….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 24 – Bioavailability
July 31 – Excipients